About Van Herk Groep
Van Herk Groep is a venture capital firm founded in 1951. It is primarily based out of Rotterdam, Netherlands. As of Dec 2025, Van Herk Groep has invested in 28 companies. It primarily invests in Seed round in Netherlands based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Pan Cancer T Overall, Van Herk Groep portfolio has seen 8 IPOs and 7 acquisitions including key companies like argenx, SciBase and Galapagos. A lot of funds co-invest with Van Herk Groep, with names like Swanbridge Capital sharing a substantial percentage of its portfolio. Van Herk Groep has team of 5 people including 1 partners.Key Metrics
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 4 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Van Herk Groep's List of Top Investments
Van Herk Groep has a portfolio of 28 companies. Their most notable investments are in Medis and Pan Cancer T.Their portfolio spans across Netherlands, United States, Belgium and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Series A, Seed and 4 more. Here is the list of top investments by Van Herk Groep:1. argenx
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
Key facts about argenx
- Founded Year: 2008
- Location: Ghent (Belgium)
- Annual Revenue: €1B+ as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $61.9M
- Employee Count: 2,315 as on Aug 31, 2026
- Investors: Venrock, BB Biotech and 21 Others
- Latest Funding Round: Post IPO, Mar 24, 2022, $*****
- Highlight: Public
2. SciBase
SciBase AB has developed a point of care device Nevisense for the detection of malignant melanoma. It is based on Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The company conducted a pivotal study in 2012 including 1,951 patients and 2,416 lesions at 22 sites in Europe and US.
Key facts about SciBase
- Founded Year: 1998
- Location: Stockholm (Sweden)
- Stage: Public
- Total Funding till date: $22.3M
- Employee Count: 54 as on Sep 30, 2026
- Investors: SEB, Omega Funds and 5 Others
- Latest Funding Round: Post IPO, May 31, 2021, $*****
- Highlight: Public
3. Galapagos
Developer of small molecule drugs for immunology and oncology. The company specialized in the discovery and development of small molecule and antibody programs in cystic fibrosis, inflammation, cancer and other indications.
Key facts about Galapagos
- Founded Year: 1999
- Location: Mechelen (Belgium)
- Annual Revenue: €100M - €500M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $136M
- Employee Count: 559 as on Sep 30, 2026
- Investors: Gilde Healthcare, Eiffel Investment Group and 17 Others
- Latest Funding Round: Post IPO, Nov 01, 2019, $*****
- Highlight: Public
4. Merus
Developer of antibody-based drugs for cancer treatment. The company develops products using bispecific antibody engineering and advanced screening technologies that engage the power of the immune system to kill cancer cells. Its products include Zenocutuzomab, Petosemtamab, and MCLA-145 for lung, pancreatic and other cancers.
Key facts about Merus
- Founded Year: 2003
- Location: Utrecht (Netherlands)
- Annual Revenue: $10M - $50M as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $156M
- Employee Count: 184 as on Sep 30, 2026
- Investors: Venrock, RA Capital Management and 16 Others
- Latest Funding Round: Post IPO, Dec 20, 2018, $*****
- Highlight: Acquired
5. BAM
Key facts about BAM
- Founded Year: 1869
- Location: Bunnik (Netherlands)
- Stage: Public
- Employee Count: 15,830 as on Sep 30, 2026
- Investors: 27th Street Capital, Van Herk Groep and 1 Other
- Latest Funding Round: Post IPO, Jun 09, 2016, $*****
- Highlight: Public
Van Herk Groep's Year-on-Year Investment Trends
Van Herk Groep has invested in 28 companies over the last 21 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in Spatium Medical and most recent follow-on round was in Pan Cancer T.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 1 | 1 |
2024 | 1 | 1 | 2 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 2 | 4 |
2020 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
Van Herk Groep's Investments by Stage
Van Herk Groep has made 5 investments in Series A stage with an average round size of $4.47M, 4 investments in Seed stage and 2 investments in Post IPO stage.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Seed | 4 |
Post IPO | 2 |
Series C | 2 |
PE | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Van Herk Groep's Investments by Sector
Van Herk Groep has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, High Tech, Sustainability Tech and Enterprise Applications. Notably, it has invested in 18 Enterprise (B2B) companies, 18 Tech companies, 6 Consumer (B2C) companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
HealthTech | 3 |
High Tech | 3 |
Sustainability Tech | 2 |
Enterprise Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Van Herk Groep's Investments by Geography
Van Herk Groep has made most investments in Netherlands (12), followed by India where it has made 1 investment.Country | No. of Investments |
|---|---|
Netherlands | 12 |
India | 1 |
Sweden | 1 |
United States | 1 |
Note: We have considered here, only first round of investments
Van Herk Groep's recent investments
Van Herk Groep has not made any investment in 2026 so far.Here are the most recent investments by Van Herk Groep:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 08, 2025 | Netherlands | Series A | 8370 | [+2] | |
Sep 11, 2024 | Netherlands | Series A | 8788 | [+2] | |
Jul 11, 2024 | Netherlands | Seed | 2582 | [+3] | |
Dec 21, 2021 | Netherlands | Seed | 7178 | ||
Oct 28, 2021 | Netherlands | Seed | 7831 | [+1] |
IPOs and Publicly Listed companies in Van Herk Groep's Portfolio
8 of Van Herk Groep's portfolio companies have become public. Eurocommercial Properties got listed on the Euronext Exchange (Euronext), in Jun 2018 at marketcap of $1.29B and SciBase got listed on the Nordic and Baltic regions (NASDAQ OMX).Here are Van Herk Groep's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 27, 2018 | May 24, 2018 | Post IPO | 9466 | |
Jun 02, 2015 | May 31, 2021 | Post IPO | 5356 | |
May 13, 2015 | - | - | 9139 | |
Jul 10, 2014 | - | - | 2216 | |
Sep 18, 2009 | - | - | 5656 |
Acquired companies in Van Herk Groep's Portfolio
7 companies from Van Herk Groep's portfolio have been acquired. The most recent acquisition was Merus in Dec 2025 by Genmab for $*****.Here are Van Herk Groep's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 12, 2025 | - | - | 7816 | |
Oct 07, 2025 | Apr 15, 2019 | Series B | 7022 | |
Nov 19, 2020 | Oct 28, 2014 | Series A | 1566 | |
Sep 27, 2019 | Mar 24, 2014 | Series C | 2002 | |
Mar 18, 2019 | - | - | 3230 |
Team profile of Van Herk Groep
Van Herk Groep has a team of 5 members located in Netherlands. Van Herk Groep's team does not sit on the board of any company as of now.Co-investors of Van Herk Groep
Over the past 21 years, 72 investors have co-invested in Van Herk Groep's portfolio companies. This includes funds and angels.
- Invested before Van Herk Groep: Thuja Capital, CapMan and 30 others have invested in rounds before Van Herk Groep. There are 2 companies where Thuja Capital has invested before Van Herk Groep and 1 company where CapMan has invested before Van Herk Groep.
- Top Co-investors of Van Herk Groep: 15 investors entered a company along with Van Herk Groep. These include investors like Swanbridge Capital (2 companies).
- Invested after Van Herk Groep: A total of 25 investors have invested in Van Herk Groep's portfolio after their investments. Top Investors include Europa (5 companies), Gilde Healthcare (2 companies) and European Innovation Council (2 companies).
Recent News related to Van Herk Groep
•
Pan Cancer T Raises €10M in FundingFinSMEs•Dec 08, 2025•Thuja Capital, Pan Cancer T, InnovationQuarter, Erasmus MC and 4 others
•
Zealand Pharma: Van Herk Investments B.V. major shareholder announcementGlobeNewswire•Oct 17, 2025•Van Herk Groep
•
Zealand Pharma: Van Herk Investments B.V. reports 10.001% shareholdingGlobeNewswire•Jul 18, 2025•Zealand Pharma, Van Herk Groep
•
Zealand Pharma completes Phase 2b obesity drug trial enrollment.GlobeNewswire•Mar 17, 2025•Zealand Pharma, Van Herk Groep
•
Dutch-based Spatium Medical bags €5M to improve patient recovery and surgical outcome in laparoscopySilicon Canals•Sep 11, 2024•Spatium Medical, InnovationQuarter, Demcon, Van Herk Groep
•
Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapiesBenzinga•Jul 11, 2024•Pan Cancer T, InnovationQuarter, Van Herk Groep, Thuja Capital and 3 others
•
SciBase raises SEK 71.2 million through two directed issuesSciBase•Aug 01, 2023•SciBase, Van Herk Groep, Vator Securities, Eversheds Sutherland
•
Mendus AB: Mendus announces receipt of financing commitments totaling up to SEK 250 million from Van Herk Investments and Negma GroupGlobeNewswire•Aug 26, 2022•Mendus, Negma Group, Van Herk Groep
•
Pan Cancer T extends seed financing roundPrivate Equity Wire•Oct 28, 2021•Pan Cancer T, Erasmus MC, Thuja Capital, Swanbridge Capital and 1 other
•
SciBase raises SEK 71.2 million through two directed issuesPR Newswire•May 31, 2021•SciBase, Van Herk Groep
